Press release summary
HALIFAX, Nova Scotia โ MedMira said Nov. 17 that the U.S. Food and Drug Administration granted Breakthrough Device designation to its Multiplo Complete Syphilis TP/nTP Antibody Test.
The point-of-care test uses the companyโs Rapid Vertical Flow technology to detect treponemal and non-treponemal antibodies from a single fingerstick whole-blood specimen. Conventional syphilis testing commonly combines these two antibody approaches to identify exposure and help assess active infection, often through separate laboratory procedures.
MedMira said the combined format is intended for settings that may have limited access to conventional laboratory infrastructure, including community health centers, outreach programs and remote locations. The companyโs product page says the test remains in clinical trials in Canada and is not yet approved there.
Why it matters: A rapid combined antibody test could reduce repeat visits and shorten the path from screening to clinical follow-up, especially where laboratory access is limited. Breakthrough Device designation provides additional FDA interaction and potentially prioritized review. It does not constitute FDA clearance or approval, and the release did not provide a U.S. launch date or complete clinical-performance data.







Leave a Reply